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Abstract
Purpose: This study evaluated the rate of change of best corrected visual acuity (BCVA), central retinal sensi-
tivity, and retinal and choroidal thickness in patients with macular edema after intravitreal bevacizumab.
Methods: This was a prospective, nonrandomized, interventional study. Thirty-four consecutive eyes (34 pa-
tients) with macular edema were included in the study. Choroidal neovascularization was present in 21 cases,
stage 1 retinal angiomatous proliferation in 6 cases, branch retinal vein occlusion in 4 cases, and diabetic edema
in 3 cases. Evaluation of BCVA (Early Treatment Diabetic Retinopathy Study [ETDRS] logarithm of the mini-
mum angle of resolution [LogMAR]), central retinochoroidal thickness (RCT) at standardized A-scan, combined
optical coherence tomography/microperimetric assessment of central retinal thickness (RT), central scotoma,
and fixation behavior was performed during 12 months after treatment. Choroidal thickness was considered as
the difference between RCT and RT. All patients received two initial intravitreal bevacizumab injections
(1.25mg/0.05mL) at a 1-month interval.
Results: BCVA and RT during follow-up were significantly better than at baseline. BCVA was improved of
0.32 – 0.3 LogMAR (P < 0.001) at month 1, 0.18 – 0.4 LogMAR (P = 0.05) at month 6, and 0.14 – 0.2 (P = 0.09) at
month 12. RT was reduced by 172.9 – 192.8 mm (P< 0.001) at month 1, 157.7 – 134.2 mm (P= 0.003) at month 6, and
164.3 – 122.3 (P= 0.002) at month 12. Mean retinal sensitivity significantly increased during the first month; it
decreased afterward, but an improvement if compared with baseline was present at each visit during follow-up.
In 23.5% of cases, a choroidal thinning was present during follow-up, and in this group visual acuity at
baseline and final visual improvement were significantly greater if compared with patients showing a choroidal
thickening.
Conclusion: Intravitreal bevacizumab for macular edema determines significant functional and anatomic im-
provement at the 12-month follow-up. Visual acuity at baseline and following treatment could be influenced by
the choroidal involvement.
Introduction
Vascular endothelial growth factor (VEGF) hasbeen shown to play a major role in stimulating angio-
genesis and vascular permeability in age-related macular
degeneration (AMD) patients,1 and in determining retinal
edema in branch and central retinal vein occlusion (BRVO,
CRVO),2 diabetic retinopathy,3 and retinal angiomatous
proliferation (RAP).4 Recently, several clinical case series and
noncontrolled studies from multiple investigators have de-
scribed the pharmacologic inhibition of all VEGF isoforms
with intravitreal bevacizumab as well as an improvement
in visual acuity after the intravitreal use of bevacizumab
for AMD-related choroidal neovascularization (CNV), dia-
betic macular edema, retinal angiomatous proliferation,
and CRVO.5–9 The early effects of bevacizumab in macular
edema, notwithstanding the etiology of the edema, were
recently investigated by other authors.10 Herein, we re-
port the 12-month anatomic and functional response in
macular edema from different etiologies after intravitreal
bevacizumab, and we focus on the changes of choroidal
thickness.
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Materials and Methods
Patient selection
Intravitreal bevacizumab was investigated in 34 consecu-
tive eyes (34 patients) with newly diagnosed macular edema
from CNV secondary to AMD (21 eyes), stage 1 RAP (6 eyes),
diabetic macular edema (3 eyes), and BRVO (4 eyes) from
December, 2007, to June, 2008. Stage 1 RAP was intended as
an intraretinal neovascularization (capillary proliferation
within the retina), according to the classification suggested
by Yannuzzi et al.4 Exclusion criteria were clinically relevant
opacities of the optic media and low-quality images obtained
with optical coherence tomography (OCT). Furthermore,
eyes with an anteroposterior axis shorter than 22mm and
longer than 23mm at immersion A-scan echography were
excluded because the maximum threshold for normality of
macular retinochoroidal thickness has been calculated to be
1.5mm in emmetropic eyes only.11 At baseline assessment
and during following visits (7 days, 1 month, 2 months, 3
months, and 6 months after first injection), investigations
included best-corrected central visual acuity (BCVA), fluo-
rescein angiography (FA), indocyanine green angiography
(ICGA) in case of CNV and RAP, OCT, and central micro-
perimetry (MP). A-scan standardized echography was per-
formed at baseline, and after 1 month, 2 months, 6 months,
and 12 months from injection. Bevacizumab (0.05mL solu-
tion prepared from Avastin 100mg/4 mL; Avastin from
Genentech, Inc., South San Francisco, CA) was administered
intravitreally in all patients through the pars plana according
to standard procedures12 at baseline and after 1 month. Each
patient was informed of the off-label status of bevacizumab,
and informed consent was obtained. Approval by the ethics
committee of the eye clinic was obtained. The study was
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki.
Study end points
The primary study end point was the rate of change of
visual acuity and central retinal thickness (RT) at OCT. Sec-
ondary study end points were: (1) changes of retinal sensi-
tivity, location and stability of fixation as measured with
combined spectral OCT/MP; (2) changes of central choroidal
thickness considered as the difference between central re-
tinochoroidal thickness as measured with A-scan standard-
ized echography and RT in the 3-mm-diameter Early
Treatment of Diabetic Retinopathy Study (ETDRS) central
ring as measured with OCT. Choroidal thickness was first
evaluated in all evaluated eyes as one single group; after-
ward it was evaluated in 21 eyes with a choroidal origin of
the edema (COE, including CNV) and in 13 eyes with a
retinal origin of the edema (ROE, including stage 1 RAP,
diabetic macular edema, BRVO).
Assessment of visual function
Best corrected visual acuity. BCVA was measured after
refraction using the ETDRS logarithm of the minimum angle
of resolution (LogMAR) scale.
Microperimetry. Fundus-related microperimetry was per-
formed using the spectral domain scanning laser ophthal-
moscope (SD-SLO)/OCT (Ophthalmic Technologies Inc.,
Toronto, Canada). SD-SLO/OCT includes an automated
tracking system to compensate in real time for any eye
movement. In the SD-SLO/OCT system, the map of retinal
sensitivity can be automatically overlapped on the OCT
retinal thickness topographic map to associate each sensi-
tivity value with a thickness value. To obtain a point-to-point
overlapping, the software takes highly detectable features on
the two maps (generally represented by vascular bifurca-
tions) as a point of reference. We used a stimulus size
equivalent to a Goldmann III test spot (size = 26 arc/min),
with a stimulus intensity ranging from 16 dB to 0 dB (10–400
apostilbs) and a grid of 29 stimuli covering the central 8 area
(centered on the fovea). A 4-2-1 double-staircase strategy was
used, and results were reported in decibels. The area was
classified as dense (or absolute) scotoma when maximum
stimulus intensity was not seen. The recorded fixation pat-
tern was classified into three categories for fixation location
(central, poor central, predominantly eccentric) and fixation
stability (stable, relatively unstable, unstable).13 In this study,
retinal sensitivity changes in the 8 central area, location and
stability of fixation were measured at each visit.
Assessment of retinal and choroidal morphology
Optical coherence tomography. To evaluate central retinal
thickness, SD-SLO/OCT was used. Spectral domain OCTs
provide an improved acquisition speed and less artefacts if
compared with time domain OCTs.14 For this study, we
evaluated the mean retinal thickness in the 3-mm-diameter
central ring of the ETDRS map.
Echographic examination. Macular retinochoroidal thick-
ness (RCT) was measured with standardized A-scan echo-
graphy at T-minus sensitivity. Ultrasonography was
performed using a Cinescan S Ophthalmic Ultrasound Sys-
tem (Quantel Medical S.A., Clermont-Ferrand, France) with
8-MHz standardized A-scan probes. To perform A-scan
echography, the probe was positioned at the corneal apex
and was maintained parallel to the optic axis at T-minus
sensitivity, to measure macular RCT in a repeatable and
accurate way.11 For each patient, the mean distance between
the retinal and the scleral spike in the macula after five re-
peated measurements was considered as indicative of mac-
ular RCT. A RCT of 1.5mm was considered as the maximum
threshold for normality in the macular area, as stated in
previous reports.11,15
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences (version 15.0, SPSS Inc., Chicago,
IL). Repeated measures analysis of variance (ANOVA) with
Dunnett correction for multiple comparisons was used to
compare follow-up to baseline data within a treatment
group. The Spearman correlation coefficient (rho) was used
to measure the strength of correlation between BCVA, retinal
sensitivity, and anatomic changes. Results were considered
significant if the P value was < 0.05.
Results
No patient was lost to follow-up. There were 16 males and
18 females with a mean age of 71 – 8.9 years (range, 43–91
years). Time from diagnosis ranged between 7 days and 40
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days (mean 18.3 days). Baseline characteristics are summa-
rized in Table 1.
No adverse events were observed during follow-up. All
patients received both injections. All scheduled examinations
were performed during the visits, except for MP, which was
not accepted by all patients at each visit to conclude the
examination. Functional and anatomic changes during fol-
low up are shown in Table 2 and Table 3.
Visual changes
Mean BCVA progressively increased during the first
month; it decreased afterward, but a significant improve-
ment if compared with baseline was present at each visit
during follow-up (Table 3, Fig. 1).
Retinal sensitivity
Mean retinal sensitivity increased significantly during the
first month; it decreased afterward, but an improvement if
compared with baseline was present at each visit during
follow-up. Low correlation was found between BCVA and
retinal sensitivity during follow-up (Table 3, Fig. 1).
Location and stability of fixation
During follow-up, the number of eyes with predominantly
central fixation was always greater than at baseline, although
a constant improvement was not present. Stability of fixation
progressively improved during the first 2 months, whereas
fixation became progressively more unstable between month
3 and month 12. However, during follow-up, both location
and stability of fixation were always better than at baseline.
Retinal thickness–choroidal thickness
A significant improvement of mean retinal thickness in the
3-mm-diameter central ring was present at each visit (Table
2, Fig. 1). Retinal thickness was reduced by 172.9– 192.8mm,
P < 0.001 at month 1, by 157.7 – 134.2mm, P = 0.003 at month
6, and by 164.2 122.2, P = 0.01 at month 12. Correlation
(Spearman rho) between central RT and BCVA during fol-
low-up was 0.4 (P< 0.001). RCT at baseline was increased,
and it significantly improved during follow-up.
Among all patients, choroidal thickness increased during
the first month from injection, decreased during the second
month, and increased again between month 3 and month 12.
However, choroidal thickness changes were not statistically
significant (Table 2). A choroidal thinning was present be-
tween baseline and month 12 in 8 cases (23.5%), whereas a
choroidal thickening was detected in 26 cases (77.5%) (Fig. 2).
If compared with patients who presented with a choroidal
thickening during follow-up, those who showed reduction
of choroidal thickness presented at baseline a significantly
better visual acuity (0.81 – 0.49 vs. 1.21 – 0.62, P = 0.04), a
lower retinal thickness (380.5 – 162.4mm vs. 546.4– 240.5mm,
P = 0.3) and a greater choroidal thickness (1.75 – 0.25mm vs.
1.39 – 0.22mm, P = 0.1). Although in the group enjoying
choroidal thinning during follow-up, the latter was pro-
gressive, in the group presenting with choroidal thickening,
the choroid thickened during the first month, improved to
values better than at baseline during the second month, and
thickened again between month 2 and month 12. In both the
group presenting with choroidal thinning and the group
presenting with choroidal thickening, an improvement of
BCVA and RT was present during follow-up. However, after
12 months, patients with a reduction of choroidal thickness
showed a greater improvement of VA (P = 0.007) and RT
(P = 0.09) if compared with patients with choroidal thicken-
ing (Fig. 2).
Evaluation according to the origin of the edema
Between the group of 21 eyes with a COE (including
choroidal neovascularization) and the group of 13 eyes with
a ROE (including stage 1 RAP, retinal vein occlusion, and
diabetic macular edema), no significant difference in BCVA,
retinal sensitivity, and location and stability of fixation at
baseline and during follow-up was present. At baseline,
retinal and choroidal thickening were present in both
groups. Significantly greater retinal thickening was present
in the group with a ROE (P = 0.02), whereas a greater cho-
roidal thickening was present in eyes with a COE, although
this difference was not significant (P = 0.8). During follow-up,
a significant retinal and choroidal thinning when compared
to baseline was present in both groups, and the differences at
each visit between the two groups were not significant.
Discussion
In this study we prospectively evaluated the anatomic and
functional changes after bevacizumab for macular edema,
the choroidal response to bevacizumab, and the influences of
the choroidal involvement on visual changes. Other authors
have evaluated the early effects of bevacizumab on macular
edema from different origins.10 To our knowledge, this is the
first reported prospective evaluation of these effects during
12 months and the first attempt to describe the choroidal
long-term changes after intravitreal bevacizumab.
Table 1. Baseline Characteristics (Mean – Standard Deviaton) of 34 Eyes Presenting with Macular Edema
n Age (years)
BCVA ETDRS
LogMAR RT (mm) RCT (mm) CT (mm)
All cases 34 71– 9 1.12 – 0.6 502.2– 232 2.0 – 0.3 1.49 – 0.3
Choroidal
neovascularization
21 70.6 – 8.6 1.07 – 0.5 443.1– 151.9 2– 0.3 1.55 – 0.2
RAP 6 73.3 – 4.2 0.98 – 0.8 646– 451.6 2.05 – 0.3 1.4 – 0.3
DME 3 76.6 – 6.3 1.08 – 0.1 410.3– 109.7 1.94 – 0.2 1.53 – 0.2
BRVO 4 65.7 – 15.8 1.35 – 0.8 657.2– 117.1 2.07 – 0.2 1.41 – 0.3
BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; LogMar, logarithm of the minimum angle of
resolution; RT, central retinal thickness; RCT, central retino-choroidal thickness; CT, central choroidal thickness; RAP, retinal angiomatous
proliferation; DME, diabetic macular edema; BRVO, branch retinal vein occlusion.
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During 12 months, an overall improvement of visual
function and RT was obtained. Visual acuity showed the
greatest improvement during the month after the first in-
jection, afterward it slowly worsened, although it was al-
ways significantly better than at baseline. A significant
improvement in BCVA and a reduction in central retinal
thickness due to the treatment with bevacizumab have been
reported in CNV from AMD,9,16 in RAP,17 diabetic macular
edema,5 and retinal vein occlusions.6,8,18,19 According to our
data, the general visual trend seems to show a greater ef-
fectiveness of the first of the two injections, and a possible
reason could be the reported tachyphylaxis and decreased
bioefficacy of bevacizumab after repeated injections.20
In this study, a combined spectral domain OCT/MP was
used. Retinal sensitivity, location, and stability of fixation
improved during follow-up, although a low correlation was
found with BCVA. Combined spectral domain OCT/MP
allows a live real-time evaluation of both morphologic and
functional retinal features in every single retinal point. In
eyes with macular edema associated with retinal vein oc-
clusion, a long-lasting rapid improvement in macular sensi-
tivity has been recently reported after intravitreal injection of
bevacizumab.21 Previous studies have suggested the hy-
pothesis that fixation instability inversely correlates to visual
acuity.22,23 Our results agree with this hypothesis, although a
strong correlation was not found.
A significant reduction of the mean retinal thickness in the
3-mm-diameter central ring as measured with OCT was
present during follow-up. As for visual acuity, the greatest
improvement of RT was present during the month following
the first injection. As also reported by other authors,24 we
found no strong correlation between the increase of BCVA
and the reduction of central RT.
To measure the central choroidal thickness, we used a
method that has been previously validated.10,11 Among all
evaluated eyes, choroidal thickness increased during the first
month, reduced between month 1 and month 2, and in-
creased again during the following months to values greater
than baseline. However, these changes were not significant.
In 77.5% of cases, a choroidal thickening was present be-
tween baseline and month 12. In this group, a choroidal
thinning was present between month 1 and month 2, and it
could represent either a late response to the first injection or a
response to the cumulative effect of the two injections. Inter-
estingly, patients that showed a choroidal thinning during
follow-up presented with a better VA and RT at baseline. Both
the group with choroidal thinning and the group with choroi-
dal thickening during follow-up showed improvement of VA
FIG. 1. Functional and anatomic changes during 12 months after intravitreal bevacizumab for macular edema (means and
95% confidence interval). (a) Changes of best corrected visual acuity (BCVA), (b) mean sensitivity in the central 8 area
compared with baseline, and (c) mean central retinal thickness (RT). ETDRS, Early Treatment of Diabetic Retinopathy Study;
logMAR, logarithm of the minimum angle of resolution; BL, baseline; M, month.
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and RT if compared with baseline. Nevertheless, patients with
a choroidal thinning showed a significantly greater visual
improvement. These findings likely suggest a role of choroidal
involvement in determining the final visual outcome.
Eyes with choroidal neovascularization were considered
as a group with a COE, whereas the eyes with stage 1 RAP,
BRVO, and diabetic edema were considered as a group with
a ROE. In both groups, retinal sensitivity and choroidal
thickness were not significantly different at baseline and
during follow-up. Retinal thickness at baseline was greater in
the group with a retinal origin of the edema, but no signifi-
cant differences were present between the two groups during
follow-up. This could suggest a minor role of the origin of
the edema (whether retinal or choroidal) on functional and
anatomical changes after intravitreal bevacizumab. On the
other hand, the choroid was thickened also in eyes where the
disease is supposed to start from the retina (as in stage 1
RAP, retinal vein occlusion, and diabetic edema). This could
suggest a choroidal involvement in any of the diseases
determining macular edema. However, whether choroidal
involvement starts with retinal involvement or is a conse-
quence of the retinal disease could not be stated.
A limitation of this prospective study is the small size of
the studied population. However, the size of the subgroups
was planned considering the prospective design of the study
and to make an evaluation of change rates rather than raw
measurement values, reducing the bias due to small group
size. Furthermore, for statistics, the eyes were grouped in
two groups only—eyes with a retinal origin of the edema
and eyes with a choroidal origin of the edema.
In conclusion, bevacizumab injection for macular edema
determines both functional and anatomic improvement at
the 12-month follow-up. Although the effects on the neu-
roretina are more evident, a choroidal response can be de-
tected and could represent a prognostic factor for final visual
outcome.
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